Business
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.\nSTATEN ISLAND, N.Y., June 20, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the Emerging Growth Conference as follows:\nDate:\nWednesday, July 12, 2023\nTime:\n12:35 p.m. Eastern Time\nYour unique link to register is: \nhttps://goto.webcasts.com/starthere.jsp?ei=1603282&tp_key=1cd1dcc46a&sti=axcp \nThis pre-recorded online event will provide current stockholders and the investment community the opportunity to receive an update on Acurx Pharmaceuticals and its current initiatives.\nThe presentation will be webcast at the aforementioned time, and archived for 30 days thereafter, via the Company's website at www.acurxpharma.com, under the Investors section.\nAbout Acurx Pharmaceuticals, Inc.\nAcurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).\nTo learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.\nForward-Looking Statements\nAny statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words \"believes,\" \"anticipates,\" \"plans,\" \"expects,\" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit f...